Cefepime 2 g Infusion Duration
Administer cefepime 2 g intravenously over approximately 30 minutes 1.
Standard Administration
The FDA-approved prescribing information clearly specifies that cefepime should be administered intravenously over approximately 30 minutes 1. This applies to all standard dosing regimens, including the 2 g dose commonly used for moderate to severe infections.
Dosing Context for 2 g Dose
The 2 g dose is indicated for:
- Moderate to severe pneumonia: 2 g IV every 8-12 hours 1
- Febrile neutropenia: 2 g IV every 8 hours 1
- Severe urinary tract infections: 2 g IV every 12 hours 1
- Complicated skin infections: 2 g IV every 12 hours 1
- Complicated intra-abdominal infections (with metronidazole): 2 g IV every 8-12 hours 1
Multiple guidelines confirm this standard infusion time across various clinical scenarios 2, 3, 4, 5.
Extended Infusion Considerations
While the standard 30-minute infusion is FDA-approved, extended infusions (3-4 hours) may be considered in specific populations to optimize pharmacokinetic/pharmacodynamic targets:
- Critically ill patients with sepsis or VAP: Extended infusions can improve time above MIC, particularly for resistant organisms 5
- Patients with augmented renal clearance: May benefit from prolonged infusions to maintain adequate drug exposure 6
- Febrile neutropenia: Recent data suggest extended infusions (1 g loading dose over 30 minutes, then 1 g every 8 hours over 4 hours) may achieve faster defervescence 7
Important Caveats
- Renal impairment: Dose adjustment is required when creatinine clearance ≤60 mL/min, but infusion duration remains 30 minutes 1
- Neurotoxicity risk: Higher doses (2 g every 8 hours) carry increased neurotoxicity risk, especially in elderly patients or those with renal dysfunction 1
- Pediatric dosing: The same 30-minute infusion time applies to pediatric patients receiving weight-based dosing 2, 4
For standard clinical practice, use the 30-minute infusion as specified in the FDA label. Consider extended infusions only in consultation with infectious disease specialists or clinical pharmacists for critically ill patients requiring pharmacokinetic optimization.